Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dofetilide

FDA-approved product (capsule, oral), marketed as Dofetilde, Dofetilide, Tikosyn.

Registered studies
22
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dofetilide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Atrial flutter
  • Cardiac arrhythmia
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiarrhythmics, class iii
FDA pharmacologic class
Antiarrhythmic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA23.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dofetilide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dofetilide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

    NCT01505296 · start 2011-12

    Registered record
    Registry ID
    NCT01505296
    Conditions
    Atrial Fibrillation
    Interventions
    Antiarrhythmic drug; Catheter ablation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2011-12
    Completion
    2014-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionAntiarrhythmic drug; Catheter ablation
    PhasePhase 4
    Registry statusWithdrawn

  • Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

    NCT00911508 · start 2009-11-13

    Registered record
    Registry ID
    NCT00911508
    Conditions
    Atrial Fibrillation; Arrhythmia
    Interventions
    Left atrial ablation; Rate or Rhythm Control Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-11-13
    Completion
    2017-12-31
    Enrolment
    2,204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Arrhythmia
    InterventionLeft atrial ablation; Rate or Rhythm Control Therapy
    PhaseNot applicable
    Registry statusCompleted

  • AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

    NCT00589303 · start 2007-12

    Registered record
    Registry ID
    NCT00589303
    Conditions
    Atrial Fibrillation; Heart Failure
    Interventions
    FDA approved rate and rhythm control drugs; AV Node ablation and device implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-12
    Completion
    2011-07
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Heart Failure
    InterventionFDA approved rate and rhythm control drugs; AV Node ablation and device implant
    PhasePhase 3
    Registry statusTerminated

  • A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

    NCT00408200 · start 2006-11

    Registered record
    Registry ID
    NCT00408200
    Conditions
    Atrial Fibrillation
    Interventions
    propafenone; flecainide; sotalol; dofetilide; Radiofrequency catheter ablation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    2008-06
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventionpropafenone; flecainide; sotalol; dofetilide +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

    NCT00578617 · start 2006-09

    Registered record
    Registry ID
    NCT00578617
    Conditions
    Atrial Fibrillation; Arrhythmia
    Interventions
    Rate Control; Ablation Therapy; Rate Control; Rate control; Rate control; Rate control; Rate Control; Rate Control; Rate Control; Rhythm Control; Rhythm control; Rhythm control; Rhythm control; Rhythm control; Rhythm control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-09
    Completion
    2010-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Arrhythmia
    InterventionRate Control; Ablation Therapy; Rate Control; Rate control +11 more
    PhaseNot applicable
    Registry statusCompleted

  • High Intensity Focused Ultrasound (HIFU) Ablation System Study

    NCT00392106 · start 2006-04

    Registered record
    Registry ID
    NCT00392106
    Conditions
    Atrial Fibrillation
    Interventions
    propafenone; flecainide; dofetilide; sotolol; Pulmonary vein ablation; Amiodarone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2006-04
    Completion
    2011-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventionpropafenone; flecainide; dofetilide; sotolol +2 more
    PhasePhase 3
    Registry statusSuspended

  • A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

    NCT00540787 · start 2003-08-01

    Registered record
    Registry ID
    NCT00540787
    Conditions
    Paroxysmal Atrial Fibrillation
    Interventions
    Radiofrequency ablation, antiarrhythmic drugs; Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; ThermoCool Radiofrequency Catheter
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-08-01
    Completion
    2006-06-01
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Atrial Fibrillation
    InterventionRadiofrequency ablation, antiarrhythmic drugs; Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; ThermoCool Radiofrequency Catheter
    PhasePhase 4
    Registry statusCompleted